Hua Medicine Issues Profit Warning: Expects RMB30.20 Million Interim Loss Without 2025 One-Off Gain

Bulletin Express

Aug 07

Hua Medicine (Hua Medicine-B) has cautioned investors that it anticipates a loss of about RMB30.20 million for the six months ended 30 June 2026, reversing from a RMB1.18 billion profit reported in the same period of 2025.

According to the company’s preliminary, unaudited figures, the swing into the red stems mainly from the absence of a one-off RMB1.24 billion release of contract liabilities recorded in 2025 after terminating a collaboration with Bayer. Stripping out this non-recurring item, the adjusted interim loss is expected to narrow by roughly RMB29.40 million year-on-year to around RMB30.20 million from RMB59.60 million, supported by higher revenue and an improved gross profit margin.

Management is finalising full interim results, scheduled for release in August 2026. Investors are advised to exercise caution when dealing in the company’s shares until the detailed report is available.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1111846140"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111846140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111846140?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111846140","market":"us","top_or_hot":-1,"title":"Hua Medicine Issues Profit Warning: Expects RMB30.20 Million Interim Loss Without 2025 One-Off Gain","media":"Bulletin Express","content":"<p>Hua Medicine (Hua Medicine-B) has cautioned investors that it anticipates a loss of about RMB30.20 million for the six months ended 30 June 2026, reversing from a RMB1.18 billion profit reported in the same period of 2025.</p>\n<p>According to the company’s preliminary, unaudited figures, the swing into the red stems mainly from the absence of a one-off RMB1.24 billion release of contract liabilities recorded in 2025 after terminating a collaboration with Bayer. Stripping out this non-recurring item, the adjusted interim loss is expected to narrow by roughly RMB29.40 million year-on-year to around RMB30.20 million from RMB59.60 million, supported by higher revenue and an improved gross profit margin.</p>\n<p>Management is finalising full interim results, scheduled for release in August 2026. Investors are advised to exercise caution when dealing in the company’s shares until the detailed report is available.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hua Medicine Issues Profit Warning: Expects RMB30.20 Million Interim Loss Without 2025 One-Off Gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHua Medicine Issues Profit Warning: Expects RMB30.20 Million Interim Loss Without 2025 One-Off Gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-07 06:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hua Medicine (Hua Medicine-B) has cautioned investors that it anticipates a loss of about RMB30.20 million for the six months ended 30 June 2026, reversing from a RMB1.18 billion profit reported in the same period of 2025.</p>\n<p>According to the company’s preliminary, unaudited figures, the swing into the red stems mainly from the absence of a one-off RMB1.24 billion release of contract liabilities recorded in 2025 after terminating a collaboration with Bayer. Stripping out this non-recurring item, the adjusted interim loss is expected to narrow by roughly RMB29.40 million year-on-year to around RMB30.20 million from RMB59.60 million, supported by higher revenue and an improved gross profit margin.</p>\n<p>Management is finalising full interim results, scheduled for release in August 2026. Investors are advised to exercise caution when dealing in the company’s shares until the detailed report is available.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02552","symbol_name":"华领医药-B","start_time":0,"source_url":"","article_id":"1111846140","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111846140","pubTimestamp":1786055177,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hua Medicine (Hua Medicine-B) has cautioned investors that it anticipates a loss of about RMB30.20 million for the six months ended 30 June 2026, reversing from a RMB1.18 billion profit reported in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02552":"华领医药-B"},"translate_title":"华医药发布盈利预警：预计2025年中期亏损3020万元，无一次性收益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02552":1},"content_text":"Hua Medicine (Hua Medicine-B) has cautioned investors that it anticipates a loss of about RMB30.20 million for the six months ended 30 June 2026, reversing from a RMB1.18 billion profit reported in the same period of 2025.\nAccording to the company’s preliminary, unaudited figures, the swing into the red stems mainly from the absence of a one-off RMB1.24 billion release of contract liabilities recorded in 2025 after terminating a collaboration with Bayer. Stripping out this non-recurring item, the adjusted interim loss is expected to narrow by roughly RMB29.40 million year-on-year to around RMB30.20 million from RMB59.60 million, supported by higher revenue and an improved gross profit margin.\nManagement is finalising full interim results, scheduled for release in August 2026. Investors are advised to exercise caution when dealing in the company’s shares until the detailed report is available.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}